USFDA24 May 2026, 06:00 pm
Aurobindo: Eugia Pharma Unit-1 classified as OAI by US FDA
AI Summary
The US FDA has classified the inspection of Unit-1 of Eugia Pharma Specialities Ltd, a wholly-owned subsidiary of Aurobindo Pharma, as "Official Action Indicated" (OAI). The inspection, which took place from February 16 to February 27, 2026, concluded with 4 observations. The company has stated that the OAI classification has no impact on its financials or operations and that they are committed to maintaining the highest quality manufacturing standards.
Key Highlights
- US FDA classifies Eugia Pharma Unit-1 as "Official Action Indicated" (OAI).
- The FDA inspection of the facility concluded with 4 observations.
- Aurobindo Pharma states the OAI classification has no financial or operational impact.
- The company is committed to maintaining high manufacturing standards.